Surgical Management of Carcinomatosis from Colorectal Cancer

 

 Buy Article Permissions and Reprints

ABSTRACT

Until recently, peritoneal carcinomatosis from colorectal cancer was a universally fatal manifestation of this cancer. However, two innovations in treatment have improved outcome for these patients. The new surgical interventions are collectively referred to as peritonectomy procedures. During these procedures, all visible cancer is removed in an attempt to leave the patient with only microscopic residual disease. Perioperative intraperitoneal chemotherapy, the second innovation, is employed to eradicate small-volume residual disease. The intraperitoneal chemotherapy is administered in the operating room with moderate hyperthermia and is referred to as heated intraoperative intraperitoneal chemotherapy. If tolerated, additional intraperitoneal chemotherapy can be administered during the first 5 postoperative days. The use of these combined treatments, cytoreductive surgery and intraperitoneal chemotherapy, improves survival, optimizes quality of life, and maximally preserves function. This article describes the natural history of colorectal cancer with carcinomatosis, the patterns of dissemination within the peritoneal cavity, and the benefits and limitations of intraperitoneal chemotherapy. Peritonectomy procedures are defined and described. Also presented are the mechanics of delivering perioperative intraperitoneal chemotherapy and the clinical assessments used to select patients who will benefit from combined treatment. The results of combined treatment for colorectal carcinomatosis are presented.

REFERENCES

• 1 Temple WJ Surgical Techniques and Outcomes. Surgical Oncology Clinics of North America Philadelphia; WB Saunders 2002
  Google Scholar
• 2 Taylor I. What constitutes good practice in surgical oncology?.  Eur J Surg Oncol. 2001;  27 517-520
  CrossrefPubMedGoogle Scholar
• 3 Sugarbaker P H. Peritonectomy procedures.  Ann Surg. 1995;  221 29-42
  CrossrefPubMedGoogle Scholar
• 4 Spratt J S, Adcock R A, Sherrill W, Tavathen S. Hyperthermia peritoneal perfusion system in canines.  Cancer Res. 1980;  40 253-255
  PubMedGoogle Scholar
• 5 Speyer J L, Sugarbaker P H, Collins J M, Dedrick R L, Klecker R W, Myers C E. Portal levels and hepatic clearance of 5-fluorouracil after intraperitoneal administration in humans.  Cancer Res. 1981;  41 1916-1922
  PubMedGoogle Scholar
• 6 Koga S, Hamazoe R, Maeta M, Shimizu N, Kanayama H, Osaki Y. Treatment of implanted peritoneal cancer in rats by continuous hyperthermic peritoneal perfusion in combination with an anticancer drug.  Cancer Res. 1984;  44 1840-1842
  PubMedGoogle Scholar
• 7 Flessner M F, Dedrick R L, Schultz J S. A distributable model of peritoneal plasma transport: theoretical considerations.  Am J Physiol. 1984;  246 R597-R607
  PubMedGoogle Scholar
• 8 Sugarbaker P H, Gianola F J, Speyer J L, Wesley R, Barofsky I, Myers C E. Prospective randomized trial of intravenous vs. peritoneal 5-FU in patients with advanced primary colon or rectal cancer.  Semin Oncol. 1985;  12(3 suppl 4) 101-111
  PubMedGoogle Scholar
• 9 Koga S, Hamazoe R, Maeta M, Shimizu N, Murakami A, Wakatsuki T. Prophylactic therapy for peritoneal recurrence of gastric cancer by continuous hyperthermic peritoneal perfusion with mitomycin C.  Cancer. 1988;  61 232-237
  CrossrefPubMedGoogle Scholar
• 10 Fujimoto S, Shrestha R D, Kokubun M et al.. Intraperitoneal hyperthermic perfusion combined with surgery effective for gastric cancer patients with peritoneal seeding.  Ann Surg. 1988;  208 36-41
  PubMedGoogle Scholar
• 11 Sugarbaker P H, Jablonski K A. Prognostic features of 51 colorectal and 130 appendiceal cancer patients with peritoneal carcinomatosis treated by cytoreductive surgery and intraperitoneal chemotherapy.  Ann Surg. 1995;  221 124-132
  PubMedGoogle Scholar
• 12 Yonemura Y, Fujimura T, Nishimura G et al.. Effects of intraoperative chemohyperthermia in patients with gastric cancer with peritoneal dissemination.  Surgery. 1996;  119 437-444
  PubMedGoogle Scholar
• 13 Yu W, Whang I, Suh I, Averbach A, Chang D, Sugarbaker P H. Prospective randomized trial of early postoperative intraperitoneal chemotherapy as an adjuvant to resectable gastric cancer.  Ann Surg. 1998;  228 347-354
  CrossrefPubMedGoogle Scholar
• 14 Moran B J, Cecil T D. The etiology, clinical presentation, and management of pseudomyxoma peritonei.  Surg Oncol Clin N Am. 2003;  12 585-603
  CrossrefPubMedGoogle Scholar
• 15 Urano M, Kuroda M, Nishimura Y. For the clinical application of thermo-chemotherapy given at mild temperatures.  Int J Hyperthermia. 1999;  15 79-107
  CrossrefPubMedGoogle Scholar
• 16 Verwaal V, van Ruth S, de Bree E et al.. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer.  J Clin Oncol. 2003;  21 3737-3743
  CrossrefPubMedGoogle Scholar
• 17 Gertsch P. A historical perspective on colorectal liver metastases and peritoneal carcinomatosis: similar results, different treatments.  Surg Oncol Clin N Am. 2003;  12 531-541
  CrossrefPubMedGoogle Scholar
• 18 Sugarbaker P H, Graves T, DeBruijn E A et al.. Rationale for early postoperative intraperitoneal chemotherapy (EPIC) in patients with advanced gastrointestinal cancer.  Cancer Res. 1990;  50 5790-5794
  PubMedGoogle Scholar
• 19 Jacquet P, Averbach A, Stephens A D et al.. Heated intraoperative intraperitoneal mitomycin C and early postoperative intraperitoneal 5-fluorouracil: pharmacokinetic studies.  Oncology. 1998;  55 130-138
  PubMedGoogle Scholar
• 20 Chu D ZJ, Lang N P, Thompson C, Osteen P K, Westbrook K C. Peritoneal carcinomatosis in non-gynecologic malignancy. A prospective study of prognostic factors.  Cancer. 1989;  63 364-367
  CrossrefPubMedGoogle Scholar
• 21 Sadeghi B, Arvieux C, Glehen O et al.. Peritoneal carcinomatosis from non-gynecologic malignancies. Results of the EVOCAPE 1 multicentric prospective study.  Cancer. 2000;  88 358-363
  CrossrefPubMedGoogle Scholar
• 22 Jayne D G, Fook S, Loi C, Seow-Choen F. Peritoneal carcinomatosis from colorectal cancer.  Br J Surg. 2002;  89 1545-1550
  CrossrefPubMedGoogle Scholar
• 23 Jones T. I want to live!. In: Erdrich L, Kenison K The Best American Short Stories 1993. New York; Houghton Mifflin 1993: 127-145
  Google Scholar
• 24 Sampson J A. Implantation peritoneal carcinomatosis of ovarian origin.  Am J Pathol. 1931;  7 423-443
  PubMedGoogle Scholar
• 25 Weiss L. Metastatic inefficiency: causes and consequences.  Cancer Rev. 1986;  3 1-24
  PubMedGoogle Scholar
• 26 Spratt J S, Edward M, Kubota T, Lindberg R, Tseng M T. Peritoneal carcinomatosis: anatomy, physiology, diagnosis, management.  Curr Probl Cancer. 1986;  10 555-585
  PubMedGoogle Scholar
• 27 Zoetmulder F AN. Modelstudies over het Colorectale Carcinoom. Amsterdam; Rodopi 1982
  Google Scholar
• 28 Autio V. The spread of intraperitoneal infection. Studies with Roentgen contrast medium.  Acto Chir Scand. 1964;  36(suppl 321) 5-31
  PubMedGoogle Scholar
• 29 Meyers M A. Distribution of intra-abdominal malignant seeding: dependency on dynamics of flow of ascitic fluid.  Am J Roentgenol Radium Ther Nucl Med. 1973;  119 198-206
  PubMedGoogle Scholar
• 30 Shimotsuma M, Shields J W, Simpson-Morgan M W et al.. Morpho-physiological function and role of omental milky spots as omentum associated lymphoid tissue (OALT) in the peritoneal cavity.  Lymphology. 1993;  26 90-101
  PubMedGoogle Scholar
• 31 Sugarbaker P H. Observations concerning cancer spread within the peritoneal cavity and concepts supporting an ordered pathophysiology. In: Sugarbaker PH Peritoneal Carcinomatosis: Principles of Management Boston; Kluwer 1996: 79-100
  Google Scholar
• 32 Carmignani C P, Sugarbaker T, Bromley C M, Sugarbaker P H. Intraperitoneal cancer dissemination: mechanisms of the patterns of spread.  Cancer Metastasis Rev. 2003;  22 465-472
  CrossrefPubMedGoogle Scholar
• 33 Archer A G, Sugarbaker P H, Jelinek J S. Radiology of peritoneal carcinomatosis. In: Sugarbaker PH Peritoneal Carcinomatosis: Principles of Management Boston; Kluwer 1996: 263-288
  Google Scholar
• 34 Jacquet P, Jelinek J S, Chang D, Koslowe P, Sugarbaker P H. Abdominal computed tomographic scan in the selection of patients with mucinous peritoneal carcinomatosis for cytoreductive surgery.  J Am Coll Surg. 1995;  181 530-538
  PubMedGoogle Scholar
• 35 Portilla A G, Sugarbaker P H, Chang D. Second-look surgery after cytoreduction and intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal cancer: analysis of prognostic factors.  World J Surg. 1999;  23 23-29
  CrossrefPubMedGoogle Scholar
• 36 Sugarbaker P H. Successful management of microscopic residual disease in large bowel cancer.  Cancer Chemother Pharmacol. 1999;  43(suppl) S15-S25
  CrossrefPubMedGoogle Scholar
• 37 Pestieau S R, Sugarbaker P H. Treatment of primary colon cancer with peritoneal carcinomatosis: comparison of concomitant vs. delayed management.  Dis Colon Rectum. 2000;  43 1341-1346
  CrossrefPubMedGoogle Scholar
• 38 Elias D, Blot F, El Otmany A et al.. Curative treatment of peritoneal carcinomatosis arising from colorectal cancer by complete resection and intraperitoneal chemotherapy.  Cancer. 2001;  92 71-76
  CrossrefPubMedGoogle Scholar
• 39 Witkamp A J, de Bree E, Kaag M M et al.. Extensive cytoreductive surgery followed by intra-operative hyperthermia intraperitoneal chemotherapy with mitomycin C in patients with carcinomatosis of colorectal cancer.  Eur J Surg. 2001;  37 979-984
  PubMedGoogle Scholar
• 40 Shen P, Levine E A, Hall J et al.. Factors predicting survival after intraperitoneal hyperthermic chemotherapy with mitomycin C after cytoreductive surgery for patients with peritoneal carcinomatosis.  Arch Surg. 2003;  138 26-33
  PubMedGoogle Scholar
• 41 Glehen O, Mithieux F, Osinsky D et al.. Surgery combined with peritonectomy procedures and intraperitoneal chemohyperthermia in abdominal cancers with peritoneal carcinomatosis: a phase II study.  J Clin Oncol. 2003;  21 799-806
  CrossrefPubMedGoogle Scholar
• 42 Verwaal V J, van Ruth S, de Bree E et al.. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal origin.  J Clin Oncol. 2003;  21 3737-3743
  CrossrefPubMedGoogle Scholar
• 43 Glehen O, Kwiatkowski F, Sugarbaker P H et al.. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study.  J Clin Oncol. 2004;  22 3284-3292
  CrossrefPubMedGoogle Scholar
• 44 Sugarbaker P H, Jablonski K A. Prognostic factors of 51 colorectal and 130 appendiceal cancer patients with peritoneal carcinomatosis treated by cytoreductive surgery and intraperitoneal chemotherapy.  Ann Surg. 1995;  221 124-132
  PubMedGoogle Scholar
• 45 Stephens A D, Alderman R, Chang D et al.. Morbidity and mortality of 200 treatments with cytoreductive surgery and hyperthermic intraoperative intraperitoneal chemotherapy using the Coliseum technique.  Ann Surg Oncol. 1999;  6 790-796
  CrossrefPubMedGoogle Scholar
• 46 Gonzalez-Bayon L, Sugarbaker P H, Gonzalez-Moreno S, de Lima Vazquez V, Alves S, Moran B J. Initiation of a program in peritoneal surface malignancy.  Surg Oncol Clin N Am. 2003;  12 741-753
  CrossrefPubMedGoogle Scholar
• 47 McQuellon R P, Loggie B W, Fleming R A et al.. Quality of life after intraperitoneal hyperthermic chemotherapy (IPHC) for peritoneal carcinomatosis.  Eur J Surg Oncol. 2001;  27 65-73
  CrossrefPubMedGoogle Scholar
• 48 Sugarbaker P H. Carcinomatosis, is cure an option?.  J Clin Oncol. 2003;  21 762-764
  CrossrefPubMedGoogle Scholar

Paul H SugarbakerM.D. 

Washington Cancer Institute, 106 Irving St.

NW, Ste. 3900, Washington, DC 20010-2975

Email: Paul.Sugarbaker@medstar.net